Lantheus Acquires Cerveau Technologies to Expands Imaging Pipeline into Alzheimer’s Disease
Shots:
- Cerveau to receive up front & is eligible to receive additional development & commercial milestones along with royalty for research revenue & commercial sales. The acquisition diversifies Lantheus’ radiopharmaceutical diagnostic imaging agent pipeline incl. Tau PET imaging agent in AD
- Cerveau’s MK-6240 is a second-generation F 18-labeled PET imaging agent targeting Tau tangles in AD & is designed to aid in diagnosing, staging & informing treatment selection & response to therapy for AD
- The therapy is currently being studied in 60+ academic and industry clinical trials globally for multiple late-stage Alzheimer’s disease therapeutic candidates
Ref: Globenewswire | Image: Lantheus
Related Post:- Lantheus Entered into an Exclusive License Agreements with POINT Biopharma to Commercialize PNT2002 and PNT2003
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
